An interventional study of Ultra low dose CT scan and Regular CT or Low Dose CT scan in Kidney Stones, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-20.
Sponsored by Yale University · Not applicable, Interventional, and Diagnostic
This is the third phase (feasibility and impact) of a three-phase project designed to derive, validate and test the feasibility and impact of implementing clinical decision support to safely limit the use of Computerized Tomography (CT) and its accompanying radiation and cost in emergency department patients with suspected renal colic.
Hypothesis: Using a before and after model, integration of a clinical prediction rule into decisions about imaging in patients with suspected renal colic will result in a reduction of between 25-50% of radiation received from CT scanning in this population, without adverse affects on patient-centered outcomes.
Patients that a clinician deems a CT Flank Pain Protocol for suspected kidney stone is warranted based on their usual practice will be eligible for enrollment. Clinicians will be encouraged to page the Research Associate (RA) prior to ordering the CT, and an automatic page will go out for all CT flank pain protocols that are ordered via EPIC. RAs will approach eligible subjects for written informed consent. Subjects who are incapable or unwilling to provide informed consent, including non-English speaking patients will be excluded.
Following written informed consent, eligibility for the S.T.O.N.E. score will be determined.
Subjects that consent to enrollment but have exclusion criteria will be enrolled observationally to determine the performance of the S.T.O.N.E. score and outcomes in these groups, but will not be eligible for alternate imaging pathways.
Subjects who do not have any of the above exclusion criteria will be placed in one of three groups based on the S.T.O.N.E. score (which may be supplemented by gestalt clinician pre-test probability and/or point-of-care ultrasound for hydronephrosis). The groups are low, moderate, or high and correspond to the likelihood of the patient having a kidney stone as described in results from phases I and II.Subjects in the "high" likelihood of stone group will be eligible to get either Ultra Low Dose Computerized Tomography (ULDCT) or "expectant management". The choice will be determined by the primary clinician in conjunction with the patient. If ULDCT is elected, the scan will be read diagnostically by the radiologist and the clinician will treat the patient based on these results. If the expectant management option is chosen, no CT will be done during the ED visit and they will be treated as if they have a kidney stone. We will attempt to contact these patients at \~1 week after their ED visit, and they will also have the option to contact our study team. If symptoms are persistent for a week or more, subjects may of course pursue further clinical care with the clinician of their choice and this will not be billed to the study.
Subjects in the "moderate" likelihood of stone group will be given the option to receive either a standard dose CT or ULDCT. Again, the decision of which imaging option to choose will be made by the primary clinician in conjunction with the patient.
In the "low" likelihood of stone group the RA will present the data from the stone score to the physician and explain that patient is unlikely to have a kidney stone and they will be advised that probability of a stone is very low and that alternate imaging choices may be warranted. If they still choose to order a CT Flank Pain Protocol they will be asked to provide reasoning and the patient will receive a regular dose CT Flank Pain Protocol.
All subjects will be followed during their Emergency Department (ED) course and follow-up care (records in EPIC), with an attempt to contact the patient at \~90 days after the initial ED visit. Outcomes will include the number of eligible patients that receive regular dose CT, ULDCT, or the expectant management option. Radiation dose received will be measured with comparison of both the expected radiation dose if regular CT had been performed in all eligible patients and using a before and after model from phases I and II. We will also follow all patients to determine the prevalence and timing of diagnosis and/or intervention for kidney stone or other pathology. We will qualitatively compare the prevalence of alternative causes of symptoms and incidental findings (and follow-up) for regular and low dose CTs.
598 studies on the registry are indexed under Kidney Calculi; 163 are open to participants now.
This study's enrollment of 264 is above the median of 90 across 461 interventional studies indexed under Kidney Calculi.
Browse Kidney Calculi studies →Yale University is the lead sponsor of 1,724 studies on the registry; 298 are open to participants now.
Of its 210 completed or terminated interventional studies of FDA-regulated products, 126 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Exclusion Criteria Patients will be excluded for any one of the following reasons: patients that are
Patients with the following will not be eligible for alternate imaging, but will be enrolled observationally:
Subjects in the "high" likelihood of stone group will be eligible to get either ULDCT or "expectant management". The choice will be determined by the primary clinician in conjunction with the patient. If ULDCT is elected, the scan will be read diagnostically by the radiologist and the clinician will treat the patient based on these results. If the expectant management option is chosen, no CT will be done during the ED visit and they will be treated as if they have a kidney stone. Participants in this group will receive Ultra low dose CT scan.
Radiation: Ultra low dose CT scan
Subjects in the "moderate" likelihood of stone group will be given the option to receive either a standard dose CT or ULDCT. Again, the decision of which imaging option to choose will be made by the primary clinician in conjunction with the patient. Participants in this group will receive regular or low dose CT scan.
Radiation: Regular CT or Low Dose CT scan
In the "low" likelihood of stone group the RA will present the data from the stone score to the physician and explain that patient is unlikely to have a kidney stone and they will be advised that probability of a stone is very low and that alternate imaging choices may be warranted. If they still choose to order a CT Flank Pain Protocol they will be asked to provide reasoning and the patient will receive a regular dose CT Flank Pain Protocol. Participants in this group will not receive imaging.
Radiation: No imaging
Ultra low dose CT scan
Regular CT or Low Dose CT scan
No imaging
Radiation Exposure (Dose-Length-Product) at Baseline
Radiation exposure at baseline was collected using the mean dose length product mGy\*cm.
Time frame: Baseline (at enrollment)
Prevalence of Urological Intervention
This measure presents the prevalence of participants needing urological intervention in each arm within 90 days.
Time frame: 90 days
| Milestone | "High" Likelihood of Stone Group | "Moderate" Likelihood of Stone Group | "Low" Likelihood of Stone Group |
|---|---|---|---|
| Started | 66 | 136 | 62 |
| Completed | 65 | 130 | 62 |
| Not completed | 1 | 6 | 0 |
Radiation exposure at baseline was collected using the mean dose length product mGy\*cm.
| mGy*cm | "High" Likelihood of Stone Group | "Moderate" Likelihood of Stone Group | "Low" Likelihood of Stone Group |
|---|---|---|---|
| Radiation Exposure (Dose-Length-Product) at Baseline | 293.5 (210.5 to 377) | 482.1 (398.2 to 566) | 915.99 (834.2 to 998) |
This measure presents the prevalence of participants needing urological intervention in each arm within 90 days.
| participants | "High" Likelihood of Stone Group | "Moderate" Likelihood of Stone Group | "Low" Likelihood of Stone Group |
|---|---|---|---|
| Prevalence of Urological Intervention | 19 | 24 | 3 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| "High" Likelihood of Stone Group | — | 0/66 (0%) | 0/66 (0%) |
| "Moderate" Likelihood of Stone Group | — | 0/136 (0%) | 0/136 (0%) |
| "Low" Likelihood of Stone Group | — | 0/62 (0%) | 0/62 (0%) |
| Age, Categorical(Participants) | "High" Likelihood of Stone Group | "Moderate" Likelihood of Stone Group | "Low" Likelihood of Stone Group | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 62 | 129 | 54 | 245 |
| >=65 years | 4 | 7 | 8 | 19 |
| Age, Continuous(years) | "High" Likelihood of Stone Group | "Moderate" Likelihood of Stone Group | "Low" Likelihood of Stone Group | Total |
|---|---|---|---|---|
| Mean | 42.2 ± 14.1 | 44.0 ± 13.7 | 46.1 ± 14.7 | 44.0 ± 14.0 |
| Sex: Female, Male(Participants) | "High" Likelihood of Stone Group | "Moderate" Likelihood of Stone Group | "Low" Likelihood of Stone Group | Total |
|---|---|---|---|---|
| Female | 15 | 58 | 45 | 118 |
| Male | 51 | 78 | 17 | 146 |
| Region of Enrollment(participants) | "High" Likelihood of Stone Group | "Moderate" Likelihood of Stone Group | "Low" Likelihood of Stone Group | Total |
|---|---|---|---|---|
| United States | 66 | 136 | 62 | 264 |
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yale University